Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Original Article
M.J. Dickinson, C. Carlo-Stella, F. Morschhauser, E. Bachy, P. Corradini, G. Iacoboni, C. Khan, T. Wróbel, F. Offner, M. Trněný, S.-J. Wu, G. Cartron, M. Hertzberg, A. Sureda, D. Perez-Callejo, L. Lundberg, J. Relf, M. Dixon, E. Clark, K. Humphrey, and M. Hutchings
N Engl J Med 2022;387:2220-2231
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation